Why the study?
Familial chylomicronemia syndrome is a rare autosomal recessive metabolic disorder, and this study aimed to show the development and results of an FCS screening program in Argentina.
Does a three-stage screening program detect familial chylomicronemia syndrome in patients with severe hypertriglyceridemia?
Does a three-stage screening program detect familial chylomicronemia syndrome in patients with severe hypertriglyceridemia?
A systematic screening program for familial chylomicronemia syndrome in patients with severe hypertriglyceridemia identified variants of uncertain significance but no confirmed pathogenic variants.
Screening severe hypertriglyceridemia may identify FCS cases; leaves open need for prospective validation before wider adoption.
Objective: Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive metabolic disorder caused by mutations related to chylomicron metabolism. The objective of this study is to show the development and results of a screening program for FCS in Argentina. Materials and methods: A cross-sectional study was performed. All patients > 18 years with a triglyceride level ≥ 1,000 mg/dL in the period from January 1, 2017 to December 31, 2021 were included. The program was developed in three stages: (1) Review of electronic records and identification of suspected laboratory cases (triglyceride level ≥ 1,000 mg/dL); (2) Identification of suspected clinical cases (all suspected laboratory cases that had no relevant secondary factors) and application of the FCS score to define probable cases (score ≥ 10); (3) Perform genetic tests in probable cases. Results: Globally, 348 suspected laboratory cases (mean age of 49.9 years, 77.3% men) were included. The median triglycerides level was 1,309 mg/dL (interquartile range 1,175-1,607 mg/dL). In total, 231 patients were categorized as suspected clinical cases. After applying the FCS score, 3% of them were classified as "very likely FCS" (probable cases). Four variants of uncertain significance have been identified. No previously reported pathogenic variants were detected. Conclusion: This study shows a screening program for the detection of FCS. Although no patient was diagnosed with FCS, we believe that more programs of these characteristics should be developed in our region, given the importance of early detection of this metabolic disorder.
No takes yet. Share an insight, caveat, or question.
Massón et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: